Skip to Content

Join the 'Graft-versus-host disease' group to help and get support from people like you.

Graft-versus-host disease News

Related terms: GVHD

Azithromycin Doesn't Prevent Lung Complication After Stem Cell Transplant

Posted 8 Aug 2017 by Drugs.com

TUESDAY, Aug. 8, 2017 – An antibiotic treatment intended to lower stem cell transplant patients' risk of developing a respiratory complication appears to have backfired. French researchers explored the potential of administering the antibiotic azithromycin before and after stem cell transplantation to limit the risk for a condition known as bronchiolitis obliterans syndrome (BOS). A significant number of blood cancer patients who undergo allogeneic stem cell transplant are at risk for developing BOS. It's a potentially deadly complication in which airflow to the lungs becomes progressively obstructed, turning routine breathing into an ordeal. Allogeneic transplants are ones where genetically similar, but not identically matched, material is transplanted. The new investigation had to be stopped prematurely – after just over a year. Preliminary indications suggested that the random pool ... Read more

Related support groups: Azithromycin, Zithromax, Upper Respiratory Tract Infection, Zithromax Z-Pak, Z-Pak, Azasite, Respiratory Tract Disease, Azithromycin Dose Pack, Zithromax IV, Zithromax TRI-PAK, Graft-versus-host disease, Azithromycin/Trovafloxacin, Zmax

Imbruvica Approval Expanded to Include Graft Versus Host Disease

Posted 3 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 2, 2017 – The U.S. Food and Drug Administration on Wednesday expanded approval for the anti-cancer drug Imbruvica (ibrutinib) to include adults with chronic graft versus host disease (cGVHD). cGVHD is a deadly condition that affects up to 70 percent of people who receive a stem cell transplant to treat cancers of the blood or bone marrow, the FDA said in a news release. The condition occurs when the transplanted cells attack healthy cells in a patient's tissues. "This approval highlights how a known treatment for cancer is finding a new use in treating a serious and life-threatening condition that may occur in patients with blood cancer who receive a stem cell transplant," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence. Use of Imbruvica to treat cGVHD was studied in a clinical trial of 42 people whose symptoms lingered despite standard ... Read more

Related support groups: Prednisone, Bleeding Disorder, Methylprednisolone, Prednisolone, Hydrocortisone, Medrol, Cortisone, Dexamethasone, Triamcinolone, Betamethasone, Budesonide, Decadron, Blood Transfusion, Entocort, Solu-Medrol, Entocort EC, Imbruvica, Florinef, Fludrocortisone, Medrol Dosepak

FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease

Posted 2 Aug 2017 by Drugs.com

August 2, 2017 – The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy for the treatment of cGVHD. cGVHD is a life-threatening condition that can occur in patients after they receive a stem cell transplant from blood or bone marrow, called hematopoietic stem cell transplantation (HSCT), to treat certain blood or bone marrow cancers. cGVHD occurs when cells from the stem cell transplant attack healthy cells in a patient’s tissues. Symptoms of cGVHD can occur in the skin, eyes, mouth, gut, liver and lungs. The condition is estimated to occur in 30-70 percent of all patients who receive HSCT. “Patients with cGVHD who do not respond to other forms of therapy—typically corticosteroids to suppr ... Read more

Related support groups: Imbruvica, Ibrutinib, Graft-versus-host disease

Donor Kidneys Rejected by Centers 7 Times on Average

Posted 27 Jul 2017 by Drugs.com

THURSDAY, July 27, 2017 – A donated kidney is turned away for transplant an average of seven times before reaching the patient who finally receives it, a new study shows. Transplant centers regularly reject kidneys based on a donor's age or perceived quality of the organ, even though these kidneys are eventually accepted and work well for people farther down the waiting list, explained lead researcher Dr. Anne Huml, a nephrologist and health disparities fellow with Case Western Reserve University in Cleveland. The centers are likely being appropriately picky in selecting organs, to ensure the greatest chance of success by carefully matching each kidney to each recipient, Huml said. "If someone's been waiting five years, why rush and take the first kidney offered when within a month they'll be offered a better kidney and their outcome will be better?" Huml said. But such hesitation can ... Read more

Related support groups: Renal Transplant, Organ Transplant - Rejection Prophylaxis, Organ Transplant, Kidney Transplant, Graft-versus-host disease, Rejection Prophylaxis

Don't Rule Out Kidneys From Elderly Donors

Posted 16 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – Healthy kidneys from elderly donors are often rejected, but even kidneys from donors 80 and older can function for years after transplantation, Italian researchers report. The results were published online Dec. 15 in the Clinical Journal of the American Society of Nephrology. "The results of this study support the use of extended criteria donors, even donors older than 80 years, but they have to be accurately selected and managed with dedicated protocols," Dr. Luigi Biancone, of the University of Turin, said in a journal news release. Researchers analyzed results of deceased donor kidney transplants performed at the Turin University Renal Transplant Center between 2003 and 2013. They focused on almost 650 transplants from so-called "extended criteria" donors – donors older than 60 and those aged 50 to 59 with certain risk factors. After a follow-up of nearly ... Read more

Related support groups: Renal Failure, Renal Transplant, Chronic Kidney Disease, Organ Transplant - Rejection Prophylaxis, Peritoneal dialysis, Organ Transplant, Kidney Transplant, Graft-versus-host disease, Rejection Prophylaxis, Hyperphosphatemia of Renal Failure

New Technique Keeps Donor Lungs Viable Longer: Study

Posted 18 Nov 2016 by Drugs.com

FRIDAY, Nov. 18, 2016 – A technique that allows lungs destined for transplants to be preserved longer works well, a new Canadian study finds. The strategy, called ex-vivo lung perfusion (EVLP), allows preservation of lungs for up to 12 hours, instead of the standard six to eight hours. "We have been using EVLP ... to assess high-risk donor lungs [less healthy] for the last decade, and almost 300 patients have benefited from this technology at our centre to date," said study author Dr. Marcelo Cypel, a thoracic surgeon at Toronto General Hospital. With standard lung transplants, "donor lungs are transported cold to the hospital where they are warmed, evaluated and then cooled again until they are transplanted into the recipient," Cypel explained. The EVLP technique, which has now become more common, allows doctors to preserve lungs for longer periods by pumping them with a solution of ... Read more

Related support groups: Organ Transplant - Rejection Prophylaxis, Organ Transplant, Organ Transplant - Rejection Reversal, Respiratory Failure, Graft-versus-host disease

Organ Transplants Linked to Higher Skin Cancer Risk

Posted 21 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 21, 2016 – People who have an organ transplant may be more likely to develop skin cancer, new research suggests. The finding applies to all transplant patients, even those who are nonwhite and dark-skinned, according to Dr. Christina Lee Chung, an associate professor of dermatology at Drexel University in Philadelphia, and colleagues. The researchers said the risk increases over time with ongoing exposure to medications that suppress the immune system to prevent organ rejection. Total-body skin exams should be a routine part of care after transplant surgery, the study authors advised. For the study, the researchers analyzed medical records of 413 organ transplant recipients, 63 percent of whom were not white. The investigators found 19 new skin cancers in 15 of the nonwhite patients. That group included six black patients, five Asians and four Hispanics. Among the ... Read more

Related support groups: Basal Cell Carcinoma, Renal Transplant, Melanoma, Skin Cancer, Melanoma - Metastatic, Organ Transplant - Rejection Prophylaxis, Squamous Cell Carcinoma, Organ Transplant, Kidney Transplant, Graft-versus-host disease, Rejection Prophylaxis, History - Skin Cancer

Obama's 3-Pronged Effort to Speed Organ Transplants

Posted 13 Jun 2016 by Drugs.com

MONDAY, June 13, 2016 – The Obama administration on Monday announced wide-ranging public and private measures to speed the wait for lifesaving organ transplants in the United States. The goals include making it easier for Americans to become organ donors and increasing the number of organ transplants. Also, almost $200 million in new investments will "facilitate breakthrough research and development," the White House said in a media release. "New breakthroughs in bioengineering, transplantation, and organ preservation can further increase the number of organ transplants and improve outcomes," the President's office said. The administration has enlisted the cooperation of dozens of corporations, universities, hospitals, foundations and patient advocacy organizations in this ongoing project. Last year, more than 30,000 transplants took place in the United States, a record number. Yet ... Read more

Related support groups: Renal Transplant, Organ Transplant - Rejection Prophylaxis, Organ Transplant, Kidney Transplant, Organ Transplant - Rejection Reversal, Graft-versus-host disease, Rejection Prophylaxis, Rejection Reversal

Cancer History May Affect Survival After Organ Transplant

Posted 22 Apr 2016 by Drugs.com

FRIDAY, April 22, 2016 – Organ transplant patients who previously had cancer may be at increased risk for new cancer and early death compared to organ recipients with no cancer history, new research suggests. The findings indicate that transplant patients with a history of cancer may need closer monitoring to detect recurrent and new cancers early, the study's senior author, Dr. Nancy Baxter, said in a news release from St. Michael's Hospital in Toronto. Baxter is chief of the hospital's General Surgery Department. She and her colleagues reviewed 33 studies that included a total of nearly 400,000 patients in 12 countries. They found that organ recipients with previous cancer were 1.5 times more likely to die prematurely from any cause than those with no previous cancer. Moreover, those with previous cancer were nearly twice as likely to develop a new cancer and had three times higher ... Read more

Related support groups: Surgery, Cancer, Renal Transplant, Organ Transplant - Rejection Prophylaxis, Kidney Transplant, Graft-versus-host disease, Rejection Reversal

Doctors Report Groundbreaking HIV-to-HIV Organ Transplants

Posted 31 Mar 2016 by Drugs.com

WEDNESDAY, March 30, 2016 – Trailblazing liver and kidney transplants from an HIV-positive donor to HIV-positive recipients were announced Wednesday by surgeons at Johns Hopkins University. "A couple of weeks ago, we performed the first HIV-to-HIV liver transplant in the world and the first HIV-to-HIV kidney transplant in the United States," Dr. Dorry Segev said during a midday media briefing. Before 2013 and passage of the HIV Organ Policy Equity Act, this kind of medical advance would not have been possible, because it was illegal for HIV-positive patients to donate organs in the United States. The act allows HIV-positive donors to donate organs to patients infected with the AIDS-causing virus, Segev said. Until the law was changed, thousands of patients with HIV in need of organ transplants often risked death while waiting for a donated organ, he said. At the same time, "we were ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Organ Transplant - Rejection Prophylaxis, Organ Transplant, Graft-versus-host disease, Rejection Prophylaxis

Racial Disparity in Kidney Transplant Outcomes Narrows: Study

Posted 5 Feb 2016 by Drugs.com

THURSDAY, Feb. 4, 2016 – Racial disparities in kidney transplant outcomes are shrinking, new research indicates. Previous studies had shown that black patients who received kidney transplants had worse outcomes compared with white patients. But a new analysis of roughly 200,000 kidney transplants revealed that the success of surgeries involving black people improved between 1990 and 2012, with fewer organ rejections and deaths among these patients. The study authors compared information on almost 64,000 black and more than 145,400 white adults who received a kidney from a living or deceased donor. The findings were published online Feb. 4 in the Journal of the American Society of Nephrology. "We hypothesized that advances in immunosuppression and post-transplant management might differentially benefit black kidney transplant recipients, who were disproportionately burdened by ... Read more

Related support groups: Renal Failure, Chronic Kidney Disease, Organ Transplant - Rejection Prophylaxis, Peritoneal dialysis, Organ Transplant, Renal Osteodystrophy, Graft-versus-host disease, Rejection Prophylaxis, Hyperphosphatemia of Renal Failure

New Kidney Transplant Drug Cuts Risk of Earlier Death: Study

Posted 28 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – A newer drug used for preventing organ rejection might improve the long-term outlook for kidney transplant recipients, a new study finds. Over seven years, patients given the drug belatacept (brand name: Nulojix) were 43 percent less likely to die or see their donor kidney fail compared to patients given an older drug called cyclosporine. Experts said the findings should encourage more doctors and patients to choose belatacept over standard anti-rejection medications. "This is a potentially transformational drug," said study lead researcher Dr. Flavio Vincenti, a transplant specialist at the University of California, San Francisco. The study – funded by the drug's maker, Bristol-Myers Squibb – was published in the Jan. 28 issue of the New England Journal of Medicine. Belatacept was first approved by the U.S. Food and Drug Administration in 2011 for ... Read more

Related support groups: Renal Failure, Kidney Infections, Restasis, Cyclosporine, Chronic Kidney Disease, Organ Transplant - Rejection Prophylaxis, Peritoneal dialysis, Organ Transplant, Neoral, Organ Transplant - Rejection Reversal, Pyelonephritis, Renal Osteodystrophy, Gengraf, Graft-versus-host disease, Rejection Prophylaxis, Sandimmune, Hyperphosphatemia of Renal Failure, Belatacept, Nulojix

Kidney Transplant Prospects Worse for Native Americans: Study

Posted 5 Dec 2015 by Drugs.com

FRIDAY, Dec. 4, 2015 – Native Americans are less likely than whites to get kidney transplants and more likely to die while waiting for a new organ, researchers say. The investigators also found that Native Americans who do receive kidney transplants have slightly lower three-year survival rates compared to whites in the United States. The results from an analysis of 16 years of national data were presented recently at a meeting of the American Society of Nephrology, in San Diego. The lower three-year survival rate "is driven primarily by the prevalence of lower-quality donors among Native Americans and a greater negative impact from such donor characteristics on survival among Native Americans," lead researcher Sarah Stith, from the University of New Mexico, and colleagues said in a society news release. "Native Americans also tend to receive transplants at centers associated with ... Read more

Related support groups: Renal Failure, Chronic Kidney Disease, Organ Transplant - Rejection Prophylaxis, Peritoneal dialysis, Organ Transplant, Organ Transplant - Rejection Reversal, Graft-versus-host disease, Rejection Prophylaxis, Rejection Reversal

Heart Transplant Mental Toll May Be Greater for Women

Posted 10 Nov 2015 by Drugs.com

TUESDAY, Nov. 10, 2015 – Women may have more mental stress after a heart transplant than men, a new study finds. Heart transplant patients with higher levels of mental stress are less likely to take medications as prescribed and are at higher risk for infection, the researchers noted. The study looked at 91 heart transplant patients, almost one-third of them women, in the first 100 days after they received their new heart. The researchers found that high levels of depression were experienced by 39 percent of women, compared to 15 percent of men. High levels of anxiety occurred in more than three-quarters of women, versus 46 percent of men. Women also felt they had less control over their health than men, according to the study that was to be presented Tuesday at the American Heart Association's annual meeting in Orlando, Fla. Health care providers should monitor heart transplant ... Read more

Related support groups: Anxiety and Stress, Heart Disease, Heart Attack, Myocardial Infarction, Organ Transplant - Rejection Prophylaxis, Organ Transplant, Ischemic Heart Disease, Graft-versus-host disease, Cardiothoracic Surgery

Rule Changes Might Lead to More Lung Transplants for Kids

Posted 5 Nov 2015 by Drugs.com

THURSDAY, Nov. 5, 2015 – Twice as many young people in the United States could get lung transplants if donor lungs were available from a wider geographic area, a new study contends. "Children are dying while waiting for an organ. Geography should be one less barrier to pediatric patients receiving a potentially lifesaving transplant," said senior study author Dr. Maryam Valapour. She is a senior lung investigator at the Cleveland Clinic's Scientific Registry of Transplant Recipients and director of Lung Transplant Outcomes. Currently, donor lungs are first offered to transplant candidates near the donor hospital. If there are no local candidates, the lungs are offered beyond the local area in 500-mile radius increments. Child candidates are given priority for child donor lungs within a 1,000-mile radius of the donor hospital, followed by teens and then adults. Teen candidates get ... Read more

Related support groups: Organ Transplant - Rejection Prophylaxis, Organ Transplant, Organ Transplant - Rejection Reversal, Respiratory Distress Syndrome, Graft-versus-host disease, Respiratory Failure, Rejection Prophylaxis

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Organ Transplant

Related Drug Support Groups

prednisone, methotrexate, cyclosporine, tacrolimus, Imbruvica, mycophenolate mofetil, ibrutinib, Deltasone, Trexall, view more... Sterapred, Liquid Pred, Sterapred DS, Methotrexate LPF Sodium, Folex PFS, Meticorten, Orasone, Prednicen-M, Prednicot